secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2026-07-29T11:06:13+00:00
Accession:  0001104659-26-087808
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure reports Q2 net loss $81.1M; AMT-130 BLA submission on track for Q3 2026
-------------------------------------------------------------------------------

- Net loss $81.1M ($1.22/share) vs $37.7M ($0.69) in Q2 2025; revenue $5.8M (+$0.5M).
- Cash $810.3M after $259M June offering; runway into 2030.
- AMT-130 BLA submission for Huntington's on track for Q3 2026; four-year data expected Sept 2026.
- AMT-260 Phase I/IIa: 3 of 6 patients had 79-100% seizure reduction; no SAEs related to drug.
- AMT-191 Fabry data: dose-dependent α-Gal A activity up to 229.6x normal; all 11 patients off ERT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/0001104659-26-087808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-087808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer